Portal de Periódicos da CAPES

PROSTATE SPECIFIC ANTIGEN PROGRESSION IN MEN WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY: RESULTS OF LONG-TERM FOLLOWUP

2004; Lippincott Williams & Wilkins; Volume: 172; Issue: 5 Linguagem: Inglês

10.1097/01.ju.0000139886.25848.4a

1527-3792

Ganesh S. Palapattu, Mohamad E. Allaf, Bruce J. Trock, Jonathan I. Epstein, Patrick C. Walsh,

Urologic and reproductive health conditions

No AccessJournal of UrologyAdult Urology: Oncology: Prostate/Testis/Penis/Urethra1 Nov 2004PROSTATE SPECIFIC ANTIGEN PROGRESSION IN MEN WITH LYMPH NODE METASTASES FOLLOWING RADICAL PROSTATECTOMY: RESULTS OF LONG-TERM FOLLOWUP GANESH S. PALAPATTU, MOHAMAD E. ALLAF, BRUCE J. TROCK, JONATHAN I. EPSTEIN, and PATRICK C. WALSH GANESH S. PALAPATTUGANESH S. PALAPATTU , MOHAMAD E. ALLAFMOHAMAD E. ALLAF , BRUCE J. TROCKBRUCE J. TROCK , JONATHAN I. EPSTEINJONATHAN I. EPSTEIN , and PATRICK C. WALSHPATRICK C. WALSH View All Author Informationhttps://doi.org/10.1097/01.ju.0000139886.25848.4aAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We examined the clinical outcome of patients with lymph node metastases found at prostatectomy with the goal to identify factors that predict freedom from prostate specific antigen (PSA) progression. Materials and Methods: We retrospectively reviewed the records of 3,264 consecutive men with clinically localized prostate cancer who underwent extended pelvic lymphadenectomy and radical prostatectomy performed by a single surgeon between April 1982 and March 2003. Patients with pathologically confirmed lymph node metastases and no history of adjuvant treatment were identified. Clinical and histopathological factors were analyzed for an association with time to PSA progression using univariate and multivariable analyses. Results: Of the 143 patients (4.4% of total) in the study with nodal involvement 24 (16.8%) were free of disease at last followup (median 6 years). Median time to failure was 2 years with PSA progression occurring as late as 11 years postoperatively in 2 patients. The 5 and 7-year PSA progression free rate in all lymph node positive patients was 26.5% and 10.9%, respectively. A 15% or greater incidence of positive nodes (p = 0.0008) and high prostatectomy Gleason score (ie score 8 to 10, p = 0.008) were independent predictors of PSA progression in multivariate Cox proportional hazards models. Seminal vesicle invasion (HR 1.45, p = 0.063) or positive surgical margins (HR 1.43, p = 0.063) were marginally significant in the multivariate model. The 5-year PSA progression-free rate was 52% in men with less than 15% positive lymph nodes, prostatectomy Gleason score 7 or less and negative seminal vesicle invasion. Conclusions: While the incidence of lymph node positive disease in patients undergoing radical prostatectomy is infrequent in the PSA era, patients with nodal involvement may experience disease progression as remote as 1 decade after surgery. Pathological factors such as the percent of positive lymph nodes, prostatectomy Gleason score and seminal vesicle invasion appear to predict an increased risk of PSA failure in this population. References 1 : Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol2003; 169: 849. Abstract, Google Scholar 2 : Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Eur Urol1997; 31: 11. Google Scholar 3 : Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol1998; 22: 1491. Google Scholar 4 : Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod Pathol1997; 10: 804. Google Scholar 5 : Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol2001; 166: 416. Link, Google Scholar 6 : Implications of volume of nodal metastasis in patients with adenocarcinoma of the prostate. J Urol1985; 133: 617. Link, Google Scholar 7 : Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment. Urology1987; 30: 427. Google Scholar 8 : Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement. Urology1982; 19: 238. Google Scholar 9 : The therapeutic role of pelvic lymphadenectomy in prostatic cancer. Urol Clin North Am1980; 7: 623. Google Scholar 10 : Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol1990; 144: 1425. Link, Google Scholar 11 : Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy. J Urol1994; 152: 1077. Link, Google Scholar 12 : Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer2001; 91: 66. Google Scholar 13 : Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol2002; 167: 528. Link, Google Scholar 14 : Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer2000; 88: 2110. Google Scholar 15 : Biochemical and pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle invasion. J Urol2003; 169: 153. Link, Google Scholar 16 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Crossref, Medline, Google Scholar 17 : Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol1997; 158: 1441. Link, Google Scholar 18 : The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol2003; 170: 1872. Link, Google Scholar From the Departments of Urology (GSP, MEA, BJT, JIE, PCW) and Pathology (JIE), The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland© 2004 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byEastham J, Auffenberg G, Barocas D, Chou R, Crispino T, Davis J, Eggener S, Horwitz E, Kane C, Kirkby E, Lin D, McBride S, Morgans A, Pierorazio P, Rodrigues G, Wong W and Boorjian S (2022) Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-UpJournal of Urology, VOL. 208, NO. 1, (19-25), Online publication date: 1-Jul-2022.Daskivich T, Luu M, Freedland S, Sandler H, Spratt D and Zumsteg Z (2021) Development and Validation of an Improved Pathological Nodal Staging System in Men with Prostate CancerJournal of Urology, VOL. 207, NO. 3, (581-591), Online publication date: 1-Mar-2022.Moschini M, Sharma V, Zattoni F, Boorjian S, Frank I, Gettman M, Thompson R, Tollefson M, Kwon E and Karnes R (2015) Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term FollowupJournal of Urology, VOL. 195, NO. 6, (1773-1778), Online publication date: 1-Jun-2016.Carlsson S, Tafe L, Chade D, Sjoberg D, Passoni N, Shariat S, Eastham J, Scardino P, Fine S and Touijer K (2012) Pathological Features of Lymph Node Metastasis for Predicting Biochemical Recurrence After Radical Prostatectomy for Prostate CancerJournal of Urology, VOL. 189, NO. 4, (1314-1319), Online publication date: 1-Apr-2013.Godoy G, von Bodman C, Chade D, Dillioglugil O, Eastham J, Fine S, Scardino P and Laudone V (2012) Pelvic Lymph Node Dissection for Prostate Cancer: Frequency and Distribution of Nodal Metastases in a Contemporary Radical Prostatectomy SeriesJournal of Urology, VOL. 187, NO. 6, (2082-2086), Online publication date: 1-Jun-2012.von Bodman C, Godoy G, Chade D, Cronin A, Tafe L, Fine S, Laudone V, Scardino P and Eastham J (2010) Predicting Biochemical Recurrence-Free Survival for Patients With Positive Pelvic Lymph Nodes at Radical ProstatectomyJournal of Urology, VOL. 184, NO. 1, (143-148), Online publication date: 1-Jul-2010.Wagner M, Sokoloff M and Daneshmand S (2007) The Role of Pelvic Lymphadenectomy for Prostate Cancer—Therapeutic?Journal of Urology, VOL. 179, NO. 2, (408-413), Online publication date: 1-Feb-2008.Boorjian S, Thompson R, Siddiqui S, Bagniewski S, Bergstralh E, Karnes R, Frank I and Blute M (2007) Long-Term Outcome After Radical Prostatectomy for Patients With Lymph Node Positive Prostate Cancer in the Prostate Specific Antigen EraJournal of Urology, VOL. 178, NO. 3, (864-871), Online publication date: 1-Sep-2007.Masterson T, Bianco F, Vickers A, DiBlasio C, Fearn P, Rabbani F, Eastham J and Scardino P (2018) The Association Between Total and Positive Lymph Node Counts, and Disease Progression in Clinically Localized Prostate CancerJournal of Urology, VOL. 175, NO. 4, (1320-1325), Online publication date: 1-Apr-2006.Petros J (2018) Sentinel Lymph Node Mapping in Prostate Cancer: Opportunities Remain to Identify Truly Positive NodesJournal of Urology, VOL. 175, NO. 2, (421-422), Online publication date: 1-Feb-2006.Maffezzini M (2018) RE: PROGNOSIS OF PATIENTS WITH LYMPH NODE POSITIVE PROSTATE CANCER FOLLOWING RADICAL PROSTATECTOMY: LONG-TERM RESULTSJournal of Urology, VOL. 174, NO. 3, (1151-1152), Online publication date: 1-Sep-2005. Volume 172Issue 5November 2004Page: 1860-1864 Advertisement Copyright & Permissions© 2004 by American Urological Association, Inc.Keywordsprostatic neoplasmslymph nodesprostatectomyprostateprostate-specific antigenMetrics Author Information GANESH S. PALAPATTU More articles by this author MOHAMAD E. ALLAF More articles by this author BRUCE J. TROCK More articles by this author JONATHAN I. EPSTEIN More articles by this author PATRICK C. WALSH More articles by this author Expand All Advertisement PDF downloadLoading ...